SOUTHBOROUGH, Mass.–(BUSINESS WIRE)–Veristat, a scientific-minded global clinical research organization (CRO), announced that Cindy Henderson has been promoted to Chief Commercial Officer (CCO) from Executive Vice President, Strategic Development. As CCO, Cindy will continue to oversee all commercial functions including strategy, proposals and contracts, business development, commercial operations and marketing, in addition to driving business expansion and executing on growth opportunities.
With over 30 years’ experience — 15 with Veristat — Cindy provides the innovative leadership necessary to support the intricate and dynamic requirements of Veristat’s growing global client base. Her ability to lend deep insight into the ideal sequence of events for clinical studies to successfully progress forward has helped clients accelerate their therapies through clinical development to regulatory approval and post-marketing.
“Cindy is held in high regard by both clients and the Veristat team. She has been instrumental in developing our strategic roadmap to address the markets growing need for high value, intellectual services. Cindy has been a key contributor to Veristat’s growth and reputation in serving Clients developing novel, life enhancing therapies.” stated Patrick Flanagan, Chief Executive Officer at Veristat. “She brings a unique blend of clinical development, customer centricity and commercial expertise to the role, essential qualities as Veristat operates in a complex and highly regulated clinical environment.”
Throughout her career, Cindy has held a variety of leadership positions within the CRO industry. During her tenure at Veristat since 2007, Cindy has led the operational teams, established a strong commercial organization, supported eight global acquisitions, and created an innovative go-to-market strategy which has solidified Veristat’s position as a premier provider of world-class clinical development and regulatory solutions. Prior to joining Veristat, Cindy served as the Senior Manager of Training, Innovations and Processes at Averion International Corporation (now ICON) and was also a leader in the integration team for several key acquisitions supporting their rapid growth. Prior to Averion, Cindy was Associate Director of Data Management at PAREXEL International Corporation.
“Working at Veristat has been the highlight of my career,” stated Cindy Henderson. “It is humbling to reflect on all we have accomplished over the past 15 years, working as an extension of our sponsors’ teams, and overcoming the challenges that present themselves through the clinical development journey. One of the things I am most proud of is the impact we have had on patients. I have had the opportunity to support bringing over 40 drugs to market, most of which address unmet medical needs. There are still so many things I want to accomplish as we continue our work in making a meaningful difference in the lives of patients around the globe.”
Cindy will continue to work out of Veristat’s Southborough, MA office.
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Veristat’s focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any clinical program’s challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.